Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRICANYL vs PROAIR RESPICLICK
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Beta-2 adrenergic receptor agonist; stimulates adenyl cyclase, increasing cyclic AMP, leading to bronchodilation.
Selective beta-2 adrenergic receptor agonist; binds to beta-2 receptors on bronchial smooth muscle, activating adenylate cyclase and increasing intracellular cyclic AMP, leading to bronchodilation.
Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease,Acute asthma exacerbation,Off-label: Management of acute hyperkalemia,Off-label: Prevention of preterm labor (terbutaline)
Treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease,Prevention of exercise-induced bronchospasm
Subcutaneous: 0.25-0.5 mg every 1-2 hours as needed; Intravenous: 0.25-0.5 mg over 1 minute, may repeat every 1-2 hours; Inhalation (metered-dose inhaler): 2 inhalations (0.4 mg) every 6 hours; Nebulized: 2.5-5 mg every 6-8 hours.
Two inhalations (180 mcg total) orally inhaled every 4 to 6 hours as needed for bronchospasm; for prevention of exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.
3-4 hours (terminal); prolonged in renal impairment (up to 8-10 hours) and in elderly patients.
Terminal elimination half-life is 3–4 hours for inhaled albuterol; systemic half-life after inhalation is approximately 3.8 hours, supporting q4-6h dosing.
Metabolized in the liver via sulfonation (sulfotransferase enzymes) and to a minor extent by catechol-O-methyltransferase (COMT).
Primarily metabolized by catechol-O-methyltransferase (COMT) and sulfatase enzymes; minor hepatic metabolism via CYP450 enzymes.
Primarily renal (60-70% as unchanged drug and metabolites); fecal elimination accounts for a minor fraction (<5%).
Primarily renal (60–70% as unchanged drug and metabolites, mainly as 4'-O-sulfate ester); biliary/fecal excretion accounts for <20%.
Approximately 25% bound to albumin.
Approximately 50–65% bound to plasma proteins (primarily albumin).
~0.6 L/kg; indicates distribution into total body water.
1.5–2.5 L/kg (large Vd indicates extensive extravascular distribution, including lung tissue).
Inhalation: ~10-20% (dependent on device and technique); Oral: ~15-20% (due to extensive first-pass metabolism).
Inhalation: 10–20% (systemic absorption from lungs and GI tract following swallowed fraction).
No specific dose adjustment recommended for renal impairment; use with caution in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to potential for increased systemic exposure.
No dosage adjustment required for renal impairment; pharmacokinetics not significantly altered.
No specific dose adjustment recommended; caution in severe hepatic impairment (Child-Pugh Class C) due to reduced clearance.
No specific dosage adjustment recommended based on Child-Pugh classification; pharmacokinetics not studied in hepatic impairment.
Subcutaneous: 5-10 mcg/kg every 1-2 hours as needed (max 0.5 mg); Intravenous: 5-10 mcg/kg over 1 minute (max 0.5 mg); Inhalation (MDI): 1-2 inhalations (0.2-0.4 mg) every 4-6 hours; Nebulized: 0.01-0.03 mg/kg (max 1 mg) every 6-8 hours.
Children 4 to 11 years: 2 inhalations (180 mcg total) orally inhaled every 4 to 6 hours as needed; for exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.
Initiate at lower end of dosing range (e.g., subcutaneous 0.125 mg); monitor for tachycardia, hypertension, and tremor; consider age-related decline in renal and hepatic function.
No specific dosage adjustment required; use caution due to potential for increased sensitivity to sympathomimetic effects; monitor for adverse effects such as tremor, tachycardia, or elevated blood pressure.
Not available
None
Paradoxical bronchospasm may occur,Cardiovascular effects (e.g., tachycardia, arrhythmias, increased blood pressure) use caution with cardiovascular disorders,Hypokalemia may occur,Hyperglycemia reported,Immediate hypersensitivity reactions
Paradoxical bronchospasm may occur, which can be life-threatening,Cardiovascular effects: increased heart rate, blood pressure, or ECG changes; use caution in patients with cardiovascular disorders,Fatalities reported with excessive use,Immediate hypersensitivity reactions (urticaria, angioedema, rash),Do not exceed recommended dose; excessive use may lead to death,Hypokalemia and hyperglycemia may occur, especially with high doses
Hypersensitivity to any component,Tachydysrhythmias,Cardiac glycoside toxicity with arrhythmias
Hypersensitivity to albuterol or any ingredient in the formulation
No significant food interactions. However, avoid excessive caffeine intake (coffee, tea, cola) as it may exacerbate beta-agonist side effects like palpitations and tremor.
No specific food interactions. Avoid xanthine-containing foods (caffeine) if experiencing excessive stimulation; however, no direct interaction with albuterol.
Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if clearly needed. First trimester: limited data suggest no major malformations. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and transient hypocalcemia. Avoid in preterm labor due to maternal and fetal adverse effects.
Pregnancy Category C. In animal studies, albuterol administered subcutaneously at doses 0.5-50 times the maximum recommended human inhalation dose (MRHID) caused cleft palate, delayed ossification, and decreased fetal weight. No adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies risk. First trimester: Risk cannot be ruled out. Second and third trimesters: Risk of maternal tachycardia, hypoglycemia, and hypokalemia; preterm labor inhibition may occur; avoid use during labor due to risk of transient fetal hypoglycemia.
Excreted into breast milk in small amounts; M/P ratio approximately 2.5. No adverse effects reported in infants at therapeutic maternal doses. However, monitor infant for signs of beta-2 adrenergic stimulation (e.g., tachycardia, irritability). Consider risk-benefit.
Albuterol is excreted into human milk in small amounts (M/P ratio not established). Estimated infant dose <1% of maternal weight-adjusted dose. No published adverse effects. Use with caution, especially in preterm infants. Monitor infant for signs of sympathetic stimulation (tachycardia, irritability).
No specific dose adjustments recommended for asthma or COPD. However, in preterm labor (off-label), use lowest effective dose and shortest duration due to increased risk of maternal pulmonary edema, cardiac ischemia, and fetal effects. Monitor closely.
No specific dose adjustment recommended for pregnant women. However, pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) may theoretically reduce systemic exposure; monitor therapeutic response. Use lowest effective dose to minimize risk of tachycardia and hypokalemia.
BRICANYL (terbutaline sulfate) is a beta-2 adrenergic agonist used for bronchodilation in asthma and COPD. It can cause transient hypokalemia, hyperglycemia, and tremor. Use with caution in patients with diabetes, hypertension, or hyperthyroidism. Monitor serum potassium in patients on diuretics or with hypoxia. Not recommended for acute severe asthma as monotherapy; prefer short-acting beta-agonists like albuterol.
PROAIR RESPICLICK is a breath-actuated inhaler containing albuterol sulfate, a short-acting beta-2 agonist (SABA). It does not require coordination between actuation and inhalation, making it suitable for patients with difficulty using traditional MDIs. Priming is needed after 7 days of non-use or if dropped; shake well before each use. Monitor for paradoxical bronchospasm and excessive use indicating poorly controlled asthma.
Use exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Shake the inhaler well before each use.,Rinse mouth with water after inhalation to prevent oral thrush.,Seek emergency medical help if breathing problems worsen or if you have chest pain or irregular heartbeat.,Monitor blood sugar if diabetic as this medication may raise blood glucose levels.,Avoid caffeine as it may increase side effects like nervousness and rapid heart rate.
Use exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Prime the inhaler with 4 test sprays into the air if not used for 7 days or after cleaning or dropping.,Shake the inhaler well before each use.,Breathe out fully, place mouthpiece in mouth, seal lips, and inhale deeply and forcefully to trigger dose delivery.,Hold breath for 10 seconds then exhale slowly.,Rinse mouth with water after each use to prevent oral thrush or throat irritation.,Seek emergency help if symptoms worsen or if relief lasts less than 3 hours.,Store at room temperature away from moisture and heat; do not puncture or incinerate.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRICANYL vs PROAIR RESPICLICK, answered by our medical review team.
BRICANYL is a Beta-2 Agonist that works by Beta-2 adrenergic receptor agonist; stimulates adenyl cyclase, increasing cyclic AMP, leading to bronchodilation.. PROAIR RESPICLICK is a Beta-2 Agonist Bronchodilator that works by Selective beta-2 adrenergic receptor agonist; binds to beta-2 receptors on bronchial smooth muscle, activating adenylate cyclase and increasing intracellular cyclic AMP, leading to bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRICANYL and PROAIR RESPICLICK depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRICANYL is: Subcutaneous: 0.25-0.5 mg every 1-2 hours as needed; Intravenous: 0.25-0.5 mg over 1 minute, may repeat every 1-2 hours; Inhalation (metered-dose inhaler): 2 inhalations (0.4 mg) every 6 hours; Nebulized: 2.5-5 mg every 6-8 hours.. The standard adult dose of PROAIR RESPICLICK is: Two inhalations (180 mcg total) orally inhaled every 4 to 6 hours as needed for bronchospasm; for prevention of exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRICANYL and PROAIR RESPICLICK in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRICANYL is classified as Category C. Insufficient human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if clearly needed. First trimester: limit. PROAIR RESPICLICK is classified as Category C. Pregnancy Category C. In animal studies, albuterol administered subcutaneously at doses 0.5-50 times the maximum recommended human inhalation dose (MRHID) caused cleft palate, dela. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.